Vanguard Scottsdale Funds has reported its financials for the period ending August 31, 2026, revealing total assets of approximately $1.7 billion. This update is significant as it underscores the fund's ongoing stability and performance in a competitive investment landscape.
The filing, dated October 29, 2026, indicates that Vanguard Scottsdale Funds, which operates under the Central Index Key 0001021882, is a well-established player in the investment management sector. The firm is incorporated in Delaware and has its business address in Valley Forge, Pennsylvania.
Background
Vanguard Scottsdale Funds is categorized as an investment entity, focusing on managing various funds and investment vehicles. The firm has undergone several filings, with the most recent ones being NPORT-P forms submitted on October 29, 2026. These filings highlight the firm's commitment to transparency and regulatory compliance, which is crucial in the investment management industry.
What the Filing Says
The recent filing states that the total assets amount to $1,704,236,520.67, with total liabilities reported at $1,575,011.17. This results in net assets of $1,702,661,509.50. The filing also includes details about the fund's performance, indicating a monthly total return of 0.1685% for the first month of reporting, followed by a decline of -1.6647% in the second month, and a recovery of 0.4342% in the third month.
Impact
This financial update is likely to affect various stakeholders, including investors, financial advisors, and competitors in the investment management sector. The stability and asset growth of Vanguard Scottsdale Funds may influence investor confidence and decisions regarding fund allocations. Competitors like Blackrock Finance Inc may also take note of Vanguard's performance as they strategize their offerings in the market.
What's Next
The filing does not specify what happens next for Vanguard Scottsdale Funds. However, the ongoing monitoring of asset performance and potential future filings will be crucial for stakeholders interested in the fund's trajectory.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






